Human RCTPubMed ID: 34162740·2021

SURMOUNT-3: Tirzepatide Efficacy in Type 2 Diabetes

Rosenstock J, Wysham C, Frías JP, et al.

Diabetes Care, 2021 · n = 731

Key finding

Tirzepatide 10mg reduced HbA1c by 2.2% versus 1.7% insulin degludec, achieved 73% with A1c <7%, and produced 7.1kg weight loss.

Summary

Phase 3 trial demonstrating tirzepatide 10mg weekly superior HbA1c reduction and weight loss compared to insulin degludec.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

TirzepatideL5

An FDA-approved dual GIP/GLP-1 receptor agonist that has shown the highest weight loss results of any approved medication.

More research on Tirzepatide

Tirzepatide vs Semaglutide Once Weekly for Weight Management (SURMOUNT-5)

New England Journal of Medicine · 2024 · Human RCT

Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2)

The Lancet · 2023 · Human RCT

Tirzepatide for Weight Management after Lifestyle Intervention (SURMOUNT-3)

Nature Medicine · 2023 · Human RCT

SURPASS-4: Tirzepatide Cardiovascular Outcomes Trial

New England Journal of Medicine · 2023 · Human RCT

Tirzepatide Reduces Sleep Apnea Severity in Obesity

Sleep Medicine Reviews · 2023 · Human Pilot